The Clinical and Immunologic Effects of Acetylcysteine in the Treatment of Chronic Abacterial Prostatitis

Gorpynchenko, I.; Нуріманов, К. Р.; Порошина, Т. В.; Savchenko, V.; Drannik, G.N.; DuBuske, L.M.

doi:10.1016/j.jaci.2019.12.821

Cited by 4 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their study also revealed that compared to quercetin, NAC is more capable of increasing sperm count and motility and decreasing the number of pathological sperm and leukocytes in the ejaculated fluid. They also reported that although both treatment modalities have an ability to reduce the concentration of pro‐inflammatory TNF‐α and increase the concentration of the anti‐inflammatory IL‐10, the positive effects of NAC were more pronounced on IL‐10 in comparison to quercetin 18 . In the present study, we also demonstrated that the addition of NAC to beta‐blockers could provide more clinical improvement in CP/CPPS symptoms.…”

Section: Discussionsupporting

confidence: 70%

“…They also revealed that anti‐inflammatory effects of NAC on prostate inflammation are at least partly related to its ability in increasing the expression of microRNA‐141 (miR‐141) with consequent regulating the Kelch‐like ECH‐associated protein 1/nuclear factor erythroid 2‐related factor 2 (Keap1/Nrf2) signaling pathway 17 . In this vein, Gorpynchenko and co‐workers in their recent clinical research compared the effectiveness of NAC at a dosage of 600 mg daily and quercetin at a dosage of 1 g per day for 4 weeks in treatment of men affected with CP/CPPS 18 . They reported that, similar to quercetin, NAC could improve the symptoms of CP/CPPS assessed by the NIH‐CPSI scale.…”

Section: Discussionmentioning

confidence: 99%

“…Support these findings, in a recent clinical trial study, NAC at a dosage of 1 g per day for 4 weeks showed comparable efficacy to quercetin in improving the symptoms of CP/CPPS in men suffering from CP/CPPS. This study also revealed that NAC could significantly decrease the plasma level of pro‐inflammatory biomarkers such as tumour necrosis factor alpha (TNF‐α) that have an essential role in prostate inflammation 18 . Further, emerging data suggest that NAC supplementation may also be helpful in managing several chronic pain conditions, in particular neuropathic pains 18‐20 .…”

Section: Introductionmentioning

confidence: 87%

“…This study also revealed that NAC could significantly decrease the plasma level of pro-inflammatory biomarkers such as tumour necrosis factor alpha (TNF-α) that have an essential role in prostate inflammation. 18 Further, emerging data suggest that NAC supplementation may also be helpful in managing several chronic pain conditions, in particular neuropathic pains. [18][19][20] So, considering the probable neuropathic nature of pain associated with CP/CPPS, 12,13 NAC treatment may also alleviate pain in patients affected with CP/CPPS.…”

Section: Introductionmentioning

confidence: 99%

“…18 Further, emerging data suggest that NAC supplementation may also be helpful in managing several chronic pain conditions, in particular neuropathic pains. [18][19][20] So, considering the probable neuropathic nature of pain associated with CP/CPPS, 12,13 NAC treatment may also alleviate pain in patients affected with CP/CPPS. However, clinical evidence addressing the potential application of NAC in the management of CP/CPPS is still limited.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Men suffering from category III chronic prostatitis may benefit from N‐acetylcysteine as an adjunct to alpha‐blockers

Yaryari

Mousavi-Bahar

Amirhassani

et al. 2022

LUTS

View full text Add to dashboard Cite

Objective: We designed this study to investigate the potential use of N-acetylcysteine (NAC) as an adjunct to alpha-blockers in the treatment of category III chronic prostatitis (CP).Methods: Sixty-three men with category III CP with a National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score of 15 or more were randomized to either the NAC treatment group or the placebo treatment group. Besides tamsulosin at a dose of 0.4 mg once daily, participants based on their allocation group received NAC or placebo at a dose of 600 mg twice daily for 12 weeks. The efficacy of the medications was assessed by measuring changes in the NIH-CPSI total score and its subscales, including pain, urinary symptoms, and quality of life.Results: Based on the general linear model analysis of the data, over the 12-week treatment, NAC+tamsulosin was statistically superior to placebo+tamsulosin in reducing the total NIH-CPSI score, pain subscore, and quality-of-life subscore (P value <.001). Further, after 12 weeks, more patients in the NAC+tamsulosin group than in the placebo+tamsulosin group met the responder criterion, defined as a decrease of at least 6 points in the NIH-CPSI total score (65.6% vs 29.0%). A more favorable outcome was also noted in the NAC+tamsulosin group regarding the number of patients reporting moderate or marked improvement in symptoms (62.5% vs 25.80%). No significant difference was seen between the groups concerning changes in urinary symptoms.Conclusions: Our study provided clinical evidence that men with category III CP might benefit from NAC treatment. Further studies are needed for the validation of these findings.

show abstract

Section: Discussionsupporting

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 87%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Men suffering from category III chronic prostatitis may benefit from N‐acetylcysteine as an adjunct to alpha‐blockers

Yaryari

Mousavi-Bahar

Amirhassani

et al. 2022

LUTS

View full text Add to dashboard Cite

show abstract

Efficacy and Safety of N-Acetylcysteine for the Management of Chronic Pain in Adults: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Objective To assess the efficacy and safety of N-acetylcysteine in the treatment of chronic pain. Methods A systematic search was carried out until April 2020 for clinical studies of N-acetylcysteine in the management of any persistent or recurrent chronic pain condition for adults ≥ 18 years old. Risk of Bias was assessed using the validated risk of bias tools. When appropriate, a meta-analysis using a random-effects model was performed, with a fixed-effect model for sensitivity analysis. Results Nine studies (n = 863) were included (5 randomized controlled trials [RCTs], 2 open-label non-comparative studies and 2 comparative studies), that evaluated patients with sickle cell disease (3), complex regional pain syndrome (1), pelvic pain/endometriosis (2), rheumatoid arthritis (1), diabetic neuropathy (1), and chronic neuropathic pain (1). In the pooled analysis of 3 RCTs, N-acetylcysteine did not reduce pain intensities (SMD -0.21, 95% CI -0.33 to 0.75, random-effects), improve functional outcomes (SMD 0.21, 95% CI -0.33 to 0.75) or quality of life (SMD 0.60, 95% CI -4.44 to 5.64); however, sensitivity analysis with a fixed effect model demonstrated an effect for pain intensities and function. Due to adverse events being inconsistently reported, no conclusion could be made regarding safety of N-acetylcysteine in chronic pain. Conclusions While there is some evidence to indicate N-acetylcysteine may provide analgesic efficacy for certain pain conditions, there is insufficient evidence to provide definitive evidence on NAC in chronic pain management. Larger-size RCTs spanning a variety of chronic pain conditions are needed to determine N-acetylcysteine’s role, if any, in pain medicine.

show abstract

N-Acetyl Cysteine as an Add-on Therapy is Useful in Treating Acute Lumbar Radiculopathy Caused by Disc Herniation: Results of a Randomized, Controlled Clinical Trial

Heidari,

Seyedian,

Mehrpooya

et al. 2023

RRCT

View full text Add to dashboard Cite

Background: Available experimental and clinical evidence indicates that N-Acetyl cysteine (NAC) may have an analgesic role in specific pain conditions, particularly neuropathic pain. Thus, we hypothesized that NAC supplementation might be also helpful in decreasing pain and improving pain-related disability in patients with acute radiculopathy. We designed this study to investigate the potential use of NAC-adjunctive treatment to Nonsteroidal Anti- Inflammatory Drugs (NSAIDs) in patients with acute radiculopathy secondary to lumbar intervertebral disc herniation. Methods: Sixty-two patients diagnosed with acute lumbar radiculopathy associated with disc herniation were randomly allocated to the NAC or the placebo groups. Besides naproxen at a dose of 500 mg twice a day, participants based on their allocation group started with NAC or matched placebo at a dose of 600 mg twice a day for eight weeks. The pain severity, measured by the Visual Analog Scale (VAS), and pain-related disability measured by the Oswestry Disability Index (ODI) were measured at baseline and weeks 2, 4, and 8 of treatment. Global improvement of symptoms rated by Patient and Clinical Global Impressions of Change (PGIC and CGIC) was also recorded at the end of week 8. All analyses were conducted on an Intentionto- Treat (ITT) analysis data set. Results: A comparison of the VAS and ODI scores at weeks 2 and 4 of the treatment between the two groups did not show a significant difference. In contrast, from week 4 to week 8, we noticed a significantly greater reduction in the mean VAS and ODI scores in the NAC group compared to the placebo group (p-value <0.001 for both variables). In parallel with these results, also, more NAC-treated than placebo-treated patients achieved treatment success defined as ‘‘very much’’ or ‘‘much improved’’ on CGIC and PGIC scales, and these differences reached a significant level (p-value = .011 and p-value = .043). Conclusion: This study suggested that NAC might be a relevant candidate for adjunct therapy in managing acute lumbar radiculopathy. Additional clinical trials are needed to validate these findings. Trial Registration: The trial was registered at Clinicaltrials.gov (identifier code: IRCT2012021 5009014N381). Registration date: 2021-02-06.

show abstract

The Clinical and Immunologic Effects of Acetylcysteine in the Treatment of Chronic Abacterial Prostatitis

Cited by 4 publications

References 0 publications

Men suffering from category III chronic prostatitis may benefit from N‐acetylcysteine as an adjunct to alpha‐blockers

Men suffering from category III chronic prostatitis may benefit from N‐acetylcysteine as an adjunct to alpha‐blockers

Efficacy and Safety of N-Acetylcysteine for the Management of Chronic Pain in Adults: A Systematic Review and Meta-Analysis

N-Acetyl Cysteine as an Add-on Therapy is Useful in Treating Acute Lumbar Radiculopathy Caused by Disc Herniation: Results of a Randomized, Controlled Clinical Trial

Contact Info

Product

Resources

About